Glaukos (GKOS) vs TransMedics Group (TMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Glaukos (GKOS) has outperformed TransMedics Group (TMDX) over the past year, gaining 84.1% versus a loss of 33.1%. Over five years, GKOS leads with a +259.9% price change compared with +197.6% for TMDX. Glaukos is the larger company by market cap ($9.51 billion vs $2.74 billion), about 3.5 times the size, while TransMedics Group is growing revenue faster (+37.1% vs +32.3%).
On valuation, TransMedics Group trades at a lower forward P/E (35.0x vs 308.1x for Glaukos). TransMedics Group converts more of its revenue into profit, with a net margin of 31.4% versus -37.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GKOS | TMDX |
|---|---|---|
| Share price | $161.29 | $79.00 |
| Market cap | $9.51B | $2.74B |
| 1-day change | -6.32% | -2.55% |
| YTD return | +42.85% | -35.06% |
| 1-year return | +84.14% | -33.08% |
| 5-year return | +259.86% | +197.55% |
| P/E ratio (TTM) | — | 20.47 |
| Forward P/E | 308.06 | 35.05 |
| EPS (TTM) | $-3.26 | $3.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $507.44M | $605.49M |
| Revenue growth (YoY) | +32.33% | +37.13% |
| Net income (latest FY) | $-187.69M | $190.29M |
| Gross margin | 55.72% | 59.92% |
| Operating margin | -39.33% | 17.93% |
| Net margin | -36.99% | 31.43% |
| 52-week high | $191.62 | $156.00 |
| 52-week low | $73.16 | $60.11 |
| Distance from 52-week high | -15.83% | -49.36% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +23.19% | +26.35% |
| Average volume | 831.71K | 820.41K |
| Shares outstanding | 58.98M | 34.68M |
| Employees | 1,094 | 898 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Glaukos is about 3.5 times larger than TransMedics Group by market value ($9.51B vs $2.74B).
- GKOS has outperformed TMDX by 117.2 percentage points over the past year.
- TransMedics Group is more profitable, keeping 31.4 cents of every revenue dollar as net income versus -37.0 cents for Glaukos.
About Glaukos
GKOS stock →Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.
Healthcare · Medical Devices · 1,094 employees
About TransMedics Group
TMDX stock →TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Healthcare · Medical Devices · 898 employees
GKOS vs TMDX FAQ
Which is bigger, Glaukos or TransMedics Group?
Glaukos (GKOS) is larger, with a market capitalization of $9.51B compared with $2.74B for TransMedics Group (TMDX).
Which stock has performed better over the past year, GKOS or TMDX?
GKOS returned +84.14% over the past 12 months, compared with -33.08% for TMDX (price return, excluding dividends). Past performance does not predict future results.
Are Glaukos and TransMedics Group in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.